|
||||||||
|
 |
 |
 |
 |
 |
 |
 |
 |
 |
 |
Select Publications
Burstein HJ, Winer EP. Aromatase inhibitors and arthralgias: A new frontier in symptom management for breast cancer survivors. J Clin Oncol 2007;25(25):3797-9. No abstract available
Buzdar A et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: Long-term safety analysis of the ATAC trial. Lancet Oncol 2006;7(8):633-43. Abstract
Carlson RW et al. Adjuvant endocrine therapy in hormone receptor-positive postmenopausal breast cancer: Evolution of NCCN, ASCO, and St Gallen recommendations. J Natl Compr Canc Netw 2006;4(10):971-9. Abstract
Coleman RE et al. Aromatase inhibitor-induced arthralgia: Clinical experience and treatment recommendations. Cancer Treat Rev 2007;[Epub ahead of print]. Abstract
Crew KD et al. Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 2007;25(25):3877-83. Abstract
Cufer T. Reducing the risk of late recurrence in hormone-responsive breast cancer. Ann Oncol 2007;18(Suppl 8):viii18-25. Abstract
Eastell R et al. Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230. J Clin Oncol 2008;26(7):1051-7. Abstract
Forbes JF et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008;9(1):45-53. Abstract
Howell A et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years’ adjuvant treatment for breast cancer. Lancet 2005;365(9453):60-2. Abstract
Kennecke HF et al. Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 2007;18(1):45-51. Abstract
Rennert G et al. Clinical outcomes of breast cancer in carriers of BRCA1 and BRCA2 mutations. N Engl J Med 2007;357(2):115-23. Abstract
Sestak I, on behalf of the ATAC Trialists’ Group. Risk factors for joint symptoms in the ATAC trial. San Antonio Breast Cancer Symposium 2007;Abstract 2071.
Singh S et al. Effect of anastrozole on bone mineral density after one year of treatment: Results from bone sub-study of the International Breast Cancer Intervention Study (IBIS-II). San Antonio Breast Cancer Symposium 2007;Abstract 28.
Thorne C. Management of arthralgias associated with aromatase inhibitor therapy. Curr Oncol 2007;14(Suppl 1):11-9. Abstract
 |
 |
EDITOR'S NOTE
Bev, BETH, BEATRICE and the next big moment in oncology
research: NSABP-C-08
Neil Love, MD
- Select publication
INTERVIEWS
Daniel F Hayes, MD
- Select publications
John F Forbes, MD
- Select publications
Julie R Gralow, MD
- Select publications
John F R Robertson,
MB, ChB, BSc, MD
- Select publications
Roundtable Discussion
- Select publications
Breast Cancer Update:
A CME Audio Series and Activity
 |
 |
 |
 |
 |
